Back to search results

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

This study is testing a new software called Risk Map Decision Support System (DSS). This software helps doctors analyze magnetic resonance imaging (MRI) scans of the prostate to better diagnose prostate cancer. You may be able to join if you are a man, 18 years or older, and are scheduled for an MRI and MRI-guided biopsy for known or suspected prostate cancer. The main goal is to see how well the Risk Map DSS tool compares to oncologists (cancer doctors) in diagnosing prostate cancer after one year. The study is currently recruiting participants.

Study design
This is an interventional study, meaning participants will receive specific interventions. It plans to enroll 180 men.
What's involved
Your participation will last about 12 months. You will have a one-time MRI and 1-2 biopsies, and then the researchers will follow your progress.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for about 12 months after the initial procedures.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05710380

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Recruiting
NAAges 18+InterventionalScreening
University of Chicago
~180 participants
Updated 2026-04-27 on ClinicalTrials.gov
What's tested:Risk Map Decision Support System (DSS).Magnetic Resonance Imaging (MRI)Magnetic Resonance Imaging (MRI) Guided Biopsy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Decision Map Tool Compared to Oncologists
Measured over 1 year

Conditions

Prostate Cancer
Prostate Adenocarcinoma
Prostate Neoplasm

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Aytekin Oto, MD · STUDY_CHAIR · University of Chicago Medicine Comprehensive Cancer Center

Who to contact

Aytekin Oto, MD
[email protected]
773-702-8553
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.
Voluntary written informed consent before the MRI examination.

Exclusion

Subjects incapable of giving informed written consent.
Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;
Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.
Prisoners.
Minor children (under the age of 18 years old).
Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.

What this trial measures

  • Decision Map Tool Compared to Oncologists1 year

    Compare the accuracy of the Risk Map Decision Support Systems (DSS) tool against the clinical accuracy of experienced radiologists in the context of the reference standard of biopsy histology.